# US 2016/0256557 A1 · Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256557 A1
- Document ID: US20160256557A1
- Status: Published application
- Kind: A1
- Application number: 14/937,689
- Filed: 2015-11-10
- Published: 2016-09-08
- Earliest claimed: 2002-05-16
- Assignees: Cti Biopharma Corp.
- Applicants: CTI BioPharma Corp.
- Inventors: Alberto Bernareggi; Valeria Livi
- Web page: https://patentgrep.com/patent/US20160256557A1

## CPC

- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.

## Claims

### Claim 1

A pharmaceutical composition comprising 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate and: i) a lactose carrier mixed with sodium chloride; or ii) a dextran carrier mixed with sodium chloride,
wherein the composition is in the form of a lyophilized powder.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the carrier is lactose.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, further comprising an antioxidant.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the weight ratio of the carrier to the sodium chloride is between 1:1 and 3:1.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the weight ratio of the 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate to the carrier is between 1:2 and 1:6.

### Claim 6

An aqueous composition comprising 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate and: i) a lactose carrier mixed with sodium chloride; or ii) a dextran carrier mixed with sodium chloride,
wherein the concentration of the 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate in the composition ranges from 7-15 mg/ml.

### Claim 7 (depends on 6)

The aqueous composition of claim 6, comprising from 10 to 40 mg/ml sodium choloride and from 20 to 60 mg/ml lactose.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a unit dose of between 25 and 200 mg of 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate.

### Claim 9 (depends on 8)

The pharmaceutical compositions of claim 8, wherein the unit dose comprises 50 mg of 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate.

### Claim 10 (depends on 1)

A kit comprising the pharmaceutical composition of claim 1, and an ampoule containing a sterile solvent suitable to reconstitute the lyophilized powder, such that the lyophilized powder is suitable for parenteral administration.

### Claim 11 (depends on 1)

A process for preparing the pharmaceutical composition of claim 1, the process comprising:
lyophilizing an aqueous solution of 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate in the presence of: i) lactose and sodium chloride; or ii) dextran and sodium chloride, wherein the step of lyophilizing comprises:
freezing the solution at a temperature below at least −45° C. for at least 3 hours;
drying the frozen solution to form a product, by increasing the temperature of the frozen solution to −35° C.±5° C. in approximately 3 hours and maintaining said temperature for at least 40 hours; and
then drying the product by increasing the temperature of the product to +30° C.±5° C. in 10 hours and maintaining said temperature for at least 8 hours.
